Genesis Therapeutics uses artificial intelligence to accelerate the development of new medicines in the pharmaceutical industry. By combining 3D spatial graph modeling and advanced molecular simulation, the company generates potential drug candidates and explores new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, exemplified by a significant deal with Eli Lilly. The company's goal is to transform drug discovery and develop effective new medicines.

Felicis

Andreessen Horowitz

JAZZ Venture Partners

Open Field Capital

Propagator Ventures

Jeffrey Rothschild

Harpoon

Menlo Ventures

T. Rowe Price

Mark Leslie

Radical Ventures

Rock Springs Capital

Ulu Ventures

BlackRock

NVentures

Fidelity Investments

AI & Machine Learning

Biotechnology

Genesis Therapeutics

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

Genesis Therapeutics Secures Nvidia Investment Boost

Genesis Therapeutics receives equity investment from NVIDIA.

Genesis Therapeutics Receives Equity Investment From NVIDIA

Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.

Genesis Therapeutics, NVIDIA Partner; $200M Boost

Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Gilead and Genesis Therapeutics announce strategic collaboration to discover and develop novel therapies.

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Foster City: Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Gilead Sciences, Genesis Therapeutics enter into strategic collaboration to discover, develop novel therapies

BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies. The annual special report features the most innovative private companies in the industry. Genesis has developed the field-leading AI platform for small molecule structure-based drug design, called Genesis Exploration of Molecular Space (GEMS), which leverages proprietary, physics-inspired generative and predictive AI methods to discover first-in-class and best-in-class molecules for challenging or previously undruggable targets. GEMS can generate novel drug-like molecules and make rapid and accurate predictions of key properties such as pose, potency, selectivity, and ADMET for highly challenging targets that lack pre-existing chemical matter as starting points for drug discovery. To date, Genesis has applied GEMS to develop a pipeline of drug programs – both wholly owned and in external collaborations – across a range of therapeutic areas. Using proceeds from its $200M Series B raise in 2023, the company plans to further advance the GEMS platform, bring forward its pipeline into clinical development, and ambitiously expand its wholly owned pipeline including in new therapeutic areas

Fierce Medtech Names Genesis Therapeutics A “Fierce 15” Company Of 2023

NVIDIA also announced several partnerships, for example, with Genesis Therapeutics, Superluminal Medicines, Inceptive, and Terray

A Look Back at JP Morgan's Healthcare Conference 2024

Editor’s Note: Eva Everloo is senior investment analyst, and Anina Troya is an investment analyst intern at agrifood tech investor PeakBridge.The views expressed in this guest commentary are the authors’ own and do not necessarily reflect those of AgFunderNews.From accelerated drug discovery and turbo-charged R&D to sparkling marketing copy and improved customer service, artificial intelligence (AI) and machine learning (ML) are being deployed in every field. But what do they bring to the food industry?In the third and final segment of a three-part deep dive into AI in food, Peakbridge explores the potential of AI to address the intersection of AI with nutrition and health.The rise of personalized nutritionChronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory conditions are the leading causes of illness, morbidity, and mortality in the United States and Europe, and constitute a significant portion of the global disease burden.In the US alone, they are responsible for 90% of the country’s $4.1 trillion annual healthcare, and they’re are on the rise, with 6 out of 10 US adults now having chronic diseases. Meanwhile, the Global Cancer Observatory (GLOBOCAN) forecasts that the global cancer burden is expected to increase to 28.4 million new cancer cases per year by 2040, with most cases occurring in low- and middle-income countries. Mental wellbeing should also be prioritized given the 13% rise in mental health conditions in the last decade.Factors exacerbating this situation include:Rise of unhealthy lifestyles: Diets low in fruits and vegetables and high in sodium and saturated fats are on the rise, alongside high rates of chronic stress, and sedentary lifestyles. Global dietary shifts: The globalization of food markets and the westernization of dietary habits have led to a surge in the availability and consumption of ultra-processed foods, pushing traditional diets to the sideline. This dietary shift has significant implications for healthcare as it affects overall well-being and health outcomes; this is exacerbated in regions where access to comprehensive healthcare and healthcare education is limited, and where there are stark economic disparities

Bytes To Bites Part Three – Wellness Wired: Leveraging Ai To Digitize Nutrition And Health

According to filings with the U.S. Securities and Exchange Commission, Genesis Therapeutics is raising $224,025,681.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Evan Feinberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About Genesis TherapeuticsGenesis Therapeutics headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization

Genesis Therapeutics Has Filed A Notice Of An Exempt Offering Of Securities To Raise $224,025,681.00 In New Equity Investment.

AI-driven drug discovery for pharmaceuticals

Genesis Therapeutics

AI-driven drug discovery for pharmaceuticals

Genesis Therapeutics

AI-driven drug discovery for pharmaceuticals

About

Simplify's Take

What believers are saying

What critics are saying

What makes Genesis Therapeutics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Genesis Therapeutics is Hiring for 0 Jobs on Simplify!